COMMONS

Impact of Brexit on patients and the life science industry examined

19 December 2017

The Health Committee hears from patient and research charities, and representatives of the pharmaceutical industry about the impact Brexit poses for the full life science process from research and development through to clinical trials, manufacture, market launch and pharmacovigilance.

Witnesses

Tuesday 19 December 2017, Grimond Room, Portcullis House

At 2.30pm

  • Professor Alan Boyd, President of Faculty of Pharmaceutical Medicine, Academy of Medical Royal Colleges
  • Emma Greenwood, Director of Policy, Cancer Research UK
  • John Maingay, Director of Policy and Public Affairs, British Heart Foundation
  • Sir Hugh Taylor, Co-Chair, Brexit Health Alliance

At 3.30pm

  • Hugo Fry, UK General Manager, Sanofi
  • Warwick Smith, Director General, British Generic Manufacturers Association
  • Phil Thompson, President, Global Affairs, GlaxoSmithKline
  • John Wilkinson, Partner, Cooley LLP 

Further information

Image: iStockphoto

More news on: Parliament, government and politics, Parliament, Health services and medicine, Medical ethics, Medicine, House of Commons news, Commons news

Share this page